Taro (river)

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Retrieved on: 
Wednesday, August 30, 2023
Neoplasm, UCSF Helen Diller Family Comprehensive Cancer Center, Portage, Thomas Jefferson University, Calendar, Clinical trial, USC Norris Comprehensive Cancer Center, Lead, G&A, Toxicity, Research, Lung cancer, ASCO, Adenosine, PRTG, Acquisition, American Society of Clinical Oncology, Patient, Washington University School of Medicine, A2A, Society, MD Anderson Cancer Center, Safety, Prostate cancer, Fiscal, Pharmaceutical industry, Coal, Taro (river)

WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023.

Key Points: 
  • WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023.
  • R&D costs increased by approximately $1.7 million to approximately $3.6 million, or approximately 89%, for the Fiscal 2024 Quarter from approximately $1.9 million in the Fiscal 2023 Quarter.
  • G&A expenses decreased by approximately $0.8 million to approximately $1.4 million, or approximately 36%, from approximately $2.2 million in the Fiscal 2023 Quarter.
  • Professional fees decreased by $0.4 million, primarily attributable to legal fees associated with the Tarus acquisition in the Fiscal 2023 Quarter.

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Retrieved on: 
Monday, July 31, 2023
IPR, Intensity, D&O, Clinical trial, Lead, G&A, Toxicity, Research, NSCLC, Lung cancer, IPhone XR, PRTG, Acquisition, University of California, Patient, UCSF, Investment, Nature, University, City, Merck, Pembrolizumab, Therapy, MD Anderson Cancer Center, Merck Sharp & Dohme Federal Credit Union, Safety, Prostate cancer, D, Pharmaceutical industry, Cryptocurrency, Life insurance, Taro (river)

R&D costs increased by approximately $1.4 million, or approximately 21%, from approximately $6.8 million in Fiscal 2022, to approximately $8.2 million in Fiscal 2023.

Key Points: 
  • R&D costs increased by approximately $1.4 million, or approximately 21%, from approximately $6.8 million in Fiscal 2022, to approximately $8.2 million in Fiscal 2023.
  • Additionally, the Company incurred additional R&D service costs totaling $0.4 million in Fiscal 2023.
  • G&A expenses decreased by approximately $0.4 million, or approximately 5%, from approximately $8.8 million in Fiscal 2022, to approximately $8.4 million in Fiscal 2023.
  • As of March 31, 2023, the Company had cash and cash equivalents of approximately $10.5 million and total current liabilities of approximately $1.9 million.

ECM PCB Stator Technology Appoints Seasoned Investment Executive Bill Warner to Board of Directors

Retrieved on: 
Tuesday, March 21, 2023
Technology, HVAC, Other Energy, Alternative Energy, Retail, Energy, EV, Electric Vehicles, Automotive, Robotics, Satellite, Vehicle Technology, Transport, Other Technology, Supply Chain Management, General Automotive, Software, Engineering, Automotive Manufacturing, Hardware, Aerospace, Electronic Design Automation, Manufacturing, Logistics, Consumer Electronics, Warner, Software as a service, Printed circuit board, CAD, Multimedia, IP, Silicon Graphics, Silicon, Stator, Symantec, PCB, Electricity, Growth, ECM, VC, Hewlett-Packard, Taro (river)

US Electric motor design and software company ECM PCB Stator Technology has appointed veteran venture capitalist and company builder Bill Warner to its Board of Directors.

Key Points: 
  • US Electric motor design and software company ECM PCB Stator Technology has appointed veteran venture capitalist and company builder Bill Warner to its Board of Directors.
  • (Photo: ECM PCB Stator Technology)
    As a company, ECM pairs its PCB Stator innovation to a software optimization platform, PrintStator , to design custom electric machines with premium operating and sustainable characteristics.
  • Bill Warner joins ECM’s Board of Directors with over three-decades of experience backing and building technology companies.
  • "ECM is excited to welcome Bill Warner to the Board of Directors.

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Retrieved on: 
Wednesday, March 1, 2023
Clinical trial, Safety, Data, Therapy, Pembrolizumab, Cancer, Society, Merck, Fiscal year, UCSF, Investigational New Drug, Insurance, University, Acquisition, Immunotherapy, Research, University of California, MD Anderson Cancer Center, Patient, D&O, Consultant, Holocene, American Society of Clinical Oncology, Merck Sharp & Dohme Federal Credit Union, Society for Immunotherapy of Cancer, NSCLC, SITC, Fiscal, Tumor microenvironment, PRTG, Nature, ASCO, Intensity, D, G&A, Pharmaceutical industry, Cryptocurrency, Life insurance, Taro (river)

WESTPORT, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced financial results for the fiscal quarter ended December 31, 2022.

Key Points: 
  • WESTPORT, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced financial results for the fiscal quarter ended December 31, 2022.
  • R&D costs increased by approximately $0.6 million, or approximately 32%, from approximately $1.9 million in the Fiscal 2022 Quarter, to approximately $2.5 million in the Fiscal 2023 Quarter.
  • The Fiscal 2022 Quarter included $0.6 million for bonuses to employees and consultants, reflected in payroll-related expenses, which was approved and paid in the Fiscal 2022 Quarter.
  • The Fiscal 2023 Quarter also included director’s fees of $0.1 million (director’s fees were approved and commenced January 2022).

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Retrieved on: 
Tuesday, November 29, 2022
MSD, Merck Sharp & Dohme Federal Credit Union, Society for Immunotherapy of Cancer, ASCO, PRTG, NSCLC, Nature, Fiscal, Quarter, Safety, Insurance, Therapy, Policy, Patient, Acquisition, CRADA, Society, Immunotherapy, American Society of Clinical Oncology, Pembrolizumab, Portage, News, Cancer, SITC, Research, Intellectual property, Development, Quality of life, Clinical trial, Survival, Research and development, IPhone XR, Pharmaceutical industry, Renewable energy, Medical device, Bank, Health insurance, Taro (river), Merck

WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.

Key Points: 
  • WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.
  • Research & development costs increased by approximately $0.2 million, or approximately 15%, from approximately $1.3 million in the Fiscal 2022 Quarter, to approximately $1.5 million in the Fiscal 2023 Quarter.
  • Additionally, the Company incurred payroll-related expenses of $0.5 million in Fiscal 2023 Quarter, compared to $0.2 million in the Fiscal 2022 Quarter.
  • General and administrative expenses increased by approximately $0.1 million, or approximately 5%, from approximately $2.0 million in the Fiscal 2022 Quarter, to approximately $2.1 million in the Fiscal 2023 Quarter.

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

Retrieved on: 
Monday, August 29, 2022
Molecule, Research and development, University, AACR, National Cancer Institute, American Society of Clinical Oncology, D, Survival, Research, CRADA, Large-cell lung carcinoma, Therapy, NASDAQ, Insurance, Nature, Adenosine, Society, Policy, LinkedIn, D&O, Quality of life, PRTG, GLOBE, Income, Cooperative research and development agreement, FDA, Company, ASCO, IPhone XR, News, Cancer, Twitter, LLC, NCI, Fiscal, B cell, Stanford University, Melanoma, National, Acquisition, Development, Patient, Vaccine, Pharmaceutical industry, Tutoring, Life insurance, Taro (river)

WESTPORT, Conn., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced financial results for the fiscal quarter ended June 30, 2022.

Key Points: 
  • Operating expenses included $1.2 million of non-cash share-based compensation expense in the Fiscal 2023 Quarter, compared to $2.2 million in the Fiscal 2022 Quarter.
  • Research & development (R&D) costs increased by approximately $0.3 million, or approximately 21%, from approximately $1.6 million in the Fiscal 2022 Quarter, to approximately $1.9 million in the Fiscal 2023 Quarter.
  • Additionally, the Company incurred payroll-related expenses of $0.4 million in Fiscal 2023 Quarter, compared to $0.2 million in the Fiscal 2022 Quarter.
  • General and administrative (G&A) expenses increased by approximately $0.2 million, or approximately 8%, from approximately $2.0 million in the Fiscal 2022 Quarter, to approximately $2.2 million in the Fiscal 2023 Quarter.

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Retrieved on: 
Wednesday, July 6, 2022
Adenocarcinoma, Patient, Immunosuppression, GLOBE, Cancer, Company, Gastrointestinal cancer, Neoplasm, IND, Quality of life, Prostate cancer, Nature, Colorectal cancer, Therapy, PRTG, Achievement, A2A, Rockefeller University, LLC, Cornell University, Immunotherapy, LPC, Twitter, Eastern Time Zone, Research, Acquisition, LinkedIn, CEO, Novartis, Harvard Medical School, Nanoparticle, Weill Cornell Medicine, Survival, NASDAQ, Board, Leadership, News, Liposome, L-Ribonucleic acid aptamer, Adenosine, International, Evaluation, Sale, TME, A2B, EVP, Lists of companies, Colchester Hospital University NHS Foundation Trust, Tumor microenvironment, Credit Suisse, Conference, Vaccine, Management, Pharmaceutical industry, Director, Venture, Taro (river)

WESTPORT, Conn., July 06, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced that it has signed an agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists. Under the terms of the agreement, Portage will acquire Tarus in exchange for 2,425,999 PRTG shares along with the assumption of $3 million of liabilities. Additionally, payments of up to $32M in Portage shares or cash would be triggered upon achievement of future development and sales milestones. As a result of the transaction, Portage acquires four best-in-class assets targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.

Key Points: 
  • As a result of the transaction, Portage acquires four best-in-class assets targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.
  • Furthermore, the potential promise of the adenosine assets, coupled with Portages highly experienced development team, underscores the rationale to partner these best-in-class assets with Portage.
  • The new assets acquired from Tarus Therapeutics include:
    TT-10 (now PORT-6): an adenosine receptor type 2A (A2A) inhibitor to treat solid tumors.
  • For more information, please visit www.portagebiotech.com , follow us on Twitter at @PortageBiotech or find us on LinkedIn atPortage Biotech Inc.